Dana dhuwit saben siji saham dianthustx.com (DNTH)

Dianthus Therapeutics (DNTH) is engaged in a high-stakes battle for leadership in autoimmune pathology therapy, leveraging its unique patents. The cash per share history on GURU.Markets contains data where the parameter mark equals 14.88. Meanwhile, a targeted approach to rare diseases ensures easy expansion of reach, while insulation from macroeconomic factors transforms the company into a reliable defensive asset.
Rincian analitis perusahaan Dianthus Therapeutics

Developing innovative subcutaneous injections to block the complement system requires significant R&D capital expenditures, making liquidity a critical survival factor for Dianthus Therapeutics (DNTH). This metric calculates the share of net cash within the structure of each share, allowing investors to assess the financial cushion and the risk of equity dilution, which clearly reflects the amount of cash per share.